Trial Profile
Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolic acid; Tacrolimus
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Therapeutic Use
- 20 Aug 2018 Status changed from active, no longer recruiting to discontinued due to difficulty in enrollement.
- 21 Nov 2011 New trial record